These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 30925538)
1. Side effects of immunotherapy: a constant challenge for oncologists. Scotté F; Ratta R; Beuzeboc P Curr Opin Oncol; 2019 Jul; 31(4):280-285. PubMed ID: 30925538 [TBL] [Abstract][Full Text] [Related]
2. The development of immunotherapy in older adults: New treatments, new toxicities? Helissey C; Vicier C; Champiat S J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796 [TBL] [Abstract][Full Text] [Related]
3. Management of immunotherapy toxicities in older adults. Bhandari S; Gill AS; Perez CA; Jain D Semin Oncol; 2018 Aug; 45(4):226-231. PubMed ID: 30446167 [TBL] [Abstract][Full Text] [Related]
5. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013 [TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients. Wood LS; Moldawer NP; Lewis C Clin J Oncol Nurs; 2019 Jun; 23(3):271-280. PubMed ID: 31099804 [TBL] [Abstract][Full Text] [Related]
7. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview. Plachouri KM; Vryzaki E; Georgiou S Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498 [TBL] [Abstract][Full Text] [Related]
8. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity. Thompson JA J Natl Compr Canc Netw; 2018 May; 16(5S):594-596. PubMed ID: 29784734 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Older Adults: A Checkpoint to Palliation? Elias R; Odejide O Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e110-e120. PubMed ID: 31099630 [TBL] [Abstract][Full Text] [Related]
10. [Toxicity of immune checkpoints inhibitors]. Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624 [TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306 [TBL] [Abstract][Full Text] [Related]
12. Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management. Ruggiero R; Di Napoli R; Balzano N; Ruggiero D; Riccardi C; Anatriello A; Cantone A; Sportiello L; Rossi F; Capuano A Expert Rev Clin Pharmacol; 2023 May; 16(5):423-434. PubMed ID: 37144360 [TBL] [Abstract][Full Text] [Related]
13. A review of the imaging manifestations of immune check point inhibitor toxicities. Thomas R; Sebastian B; George T; Majeed NF; Akinola T; Laferriere SL; Braschi-Amirfarzan M Clin Imaging; 2020 Aug; 64():70-79. PubMed ID: 32334270 [TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. Hansen ED; Wang X; Case AA; Puzanov I; Smith T J Pain Symptom Manage; 2018 Sep; 56(3):460-472. PubMed ID: 29792979 [TBL] [Abstract][Full Text] [Related]
16. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. Sibaud V Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113 [TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Graus F; Dalmau J Nat Rev Clin Oncol; 2019 Sep; 16(9):535-548. PubMed ID: 30867573 [TBL] [Abstract][Full Text] [Related]
18. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition. Pan PC; Haggiagi A Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. Inthagard J; Edwards J; Roseweir AK Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159 [TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and Treatment Recommendation and Exploration for Critical and Refractory Adverse Effects Related to Immunocheckpoint Inhibitors]. Wang H; Song P; Si X; Guo X; Li Y; Zhou J; Duan L; Zhang L; Wang M; Zhang L Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):605-614. PubMed ID: 31650941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]